Phase I study of anti-epidermal growth factor receptor antibody-drug conjugate serclutamab talirine: Safety, pharmacokinetics, and antitumor activity in advanced glioblastoma

BACKGROUND: Serclutamab talirine (Ser-T, formerly ABBV-321) is an antibody-drug conjugate consisting of an antibody (AM-1-ABT-806) directed against activated epidermal growth factor receptor (EGFR) and a pyrrolobenzodiazepine dimer. We investigated Ser-T monotherapy in a phase I, first-in-human, dos...

Descripción completa

Detalles Bibliográficos
Autores principales: Carneiro, Benedito A, Papadopoulos, Kyriakos P, Strickler, John H, Lassman, Andrew B, Waqar, Saiama N, Chae, Young Kwang, Patel, Jyoti D, Shacham-Shmueli, Einat, Kelly, Karen, Khasraw, Mustafa, Bestvina, Christine M, Merrell, Ryan, Huang, Kevin, Atluri, Harisha, Ansell, Peter, Li, Rachel, Jin, Janet, Anderson, Mark G, Reilly, Edward B, Morrison-Thiele, Gladys, Patel, Kalpesh, Robinson, Randy R, Aristide, Martha R Neagu, Gan, Hui K
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Investigations
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940695/
https://www.ncbi.nlm.nih.gov/pubmed/36814898
http://dx.doi.org/10.1093/noajnl/vdac183

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9940695/
https://www.ncbi.nlm.nih.gov/pubmed/36814898
http://dx.doi.org/10.1093/noajnl/vdac183

Ejemplares similares